Make a note of our new URL: www.brjdermatol.org!
British Journal of Dermatology
An Official Journal of the British Association of Dermatologists
Edited by:
Dr John English, Nottingham, UK
ISI Journal Citation Reports® Ranking: 2008: 4/43 Dermatology
Impact Factor: 3.489
Publishing a unique balance of basic science and clinical research
First choice in dermatology
- One of the top dermatology journals in the world - 2008 Impact Factor - 3.489
- High quality original research of instant importance - 2008 Immediacy Index - 0.761
Speed of Publication
- Rapid, robust peer review - average 15 days from submission to first decision
- Immediate 'preprint' publication upon article acceptance
- 70 days from receipt at publisher to print publication
- No page or colour charges
- Fully compliant with NIH Public Access Policy
International Readership
- Available in more than 5,000 medical and scientific libraries worldwide
- >80,000 page views per month
- Free e-alerts or RSS feeds for all registered users
- OnlineOpen - articles 'open access' upon payment of a one time author fee
Join the ranks of the best authors in the world and submit your next paper to BJD
British Journal of Dermatology publishes papers on all aspects of the biology and pathology of the skin. Originally the Journal, founded in 1888, was devoted almost exclusively to the interests of the dermatologist in clinical practice. However, the rapid development, since the 1950s, of research on the physiology and experimental pathology of the skin has been reflected in the contents of the Journal, which now provides a vehicle for the publication of both experimental and clinical ethical research and serves equally the laboratory worker and the clinician.
TopNews and Announcements
NEW - 'preprint' publication service
Further to acceptance in BJD, manuscripts are now published online immediately. AcceptedArticles are in the public domain, and citable by DOI
Articles published online ahead of print
Articles which have been fully copy-edited and peer-reviewed are published online through our Early View feature before the print edition of this journal is published
NIH Public Access Mandate
BJD is fully compliant with NIH Public Access Policy. Manuscripts will be deposited to PubMed Central (PMC) on authors' behalves. Click here for more information
Online content now available back to Volume 29 (1917)
Back issues of this journal are now available online. For further information on how to access these issues please visit our Librarian Site
Free access in the developing world
Free online access to this journal is available within institutions in the developing world through the HINARI initiative with the World Health Organization (WHO)
TopHighlights
Limited FREE access to a selection of the top-cited articles from 2007
Psoriasis: a possible risk factor for development of coronary artery calcification
Ludwig RJ, Herzog C, Rostock A, et al.
Volume: 156 Issue: 2 Pages: 271-276 Published: FEB 2007
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists
Lee HH, Song IH, Friedrich M, et al.
Volume: 156 Issue: 3 Pages: 486-491 Published: MAR 2007
Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review
Sterry W, Strober BE, Menter A
Volume: 157 Issue: 4 Pages: 649-655 Published: OCT 2007
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study
Gisondi P, Tessari G, Conti A, et al.
Volume: 157 Issue: 1 Pages: 68-73 Published: JUL 2007
Rituximab in autoimmune bullous diseases: mixed responses and adverse effects
Schmidt E, Seitz CS, Benoit S, et al.
Volume: 156 Issue: 2 Pages: 352-356 Published: FEB 2007
Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head
Alomar A, Bichel J, McRae S
Volume: 157 Issue: 1 Pages: 133-141 Published: JUL 2007
A systematic review of the safety of topical therapies for atopic dermatitis
Callen J, Chamlin S, Eichenfield LF, et al.
Volume: 156 Issue: 2 Pages: 203-221 Published: FEB 2007
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment
Meier F, Busch S, Lasithiotakis K, et al.
Volume: 156 Issue: 6 Pages: 1204-1213 Published: JUN 2007
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma
Green DS, Bodman-Smith MD, Dalgleish AG, et al.
Volume: 156 Issue: 2 Pages: 337-345 Published: FEB 2007
